Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment

AIDS

Volumn 20, Issue 6, 2006, Pages 813-820

  Kvale, Dag ^a   Ormaasen, Vidar ^a   Kran, Anne Marte Bakken ^a   Johansson, Carl Christian ^b   Aukrust, Pål ^b   Aandahl, Einar Martin ^b   Frøland, Stig S ^b   Taskén, Kjetil ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Clinical trial; Combination antiretroviral treatment; Cyclooxygenase type 2; Cyclooxygenase type 2 inhibitors; HIV; Perforin; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CD27 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN SUBCLASS; PERFORIN; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROFECOXIB;

ADULT; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 33646710893     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000218544.54586.f1     Document Type: Article

References (26)

1. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
2. Hazenberg MD, Otto SA, van Bethem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
3. Vang T, Torgersen KM, Sundvoll V, Saxena M, Levy FO, Skålhegg BS, et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signalling through the T cell receptor. J Exp Med 2001; 193:497-507.
4. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Hořejší V, Schraven B, et al. Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem 2001; 276:29313-29318.
5. Yaqub S, Abrahamsen H, Zimmermann B, Kholod N, Torgersen KM, Mustelin T, et al. Requirement of the SH3-domain for protein kinase A-mediated activation of C-terminal Src kinase (Csk). Biochem J 2003; 372:271-278.
6. Abrahamsen H, Vang T, Taskén K. Protein kinase A intersects Src signalling in detergent resistant membranes. J Biol Chem 2003; 278:17170-17177.
7. Vang T, Abrahamsen H, Myklebust S, Horejsí V, Taskén K. Combined spatial and catalytical regulation of Csk by cAMP and protein kinase A inhibits TCR signaling. J Biol Chem 2003; 278:17597-17600.
8. Aandahl EM, Moretto VVJ, Haslett PA, Bryn T, Vang T, Taskén K, et al. Inhibition of antigen specific T cell proliferation and cytokine production by PKA type I. J Immunol 2002; 169:802-808.
9. Aandahl EM, Aukrust P, Skålhegg BS, Müller F, Frøland S, Hansson V, et al. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 1998; 12:855-862.
10. Aandahl EM, Aukrust P, Müller F, Hansson V, Taskén K, Frøland SS. Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 1999; 13:F109-F114.
11. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Taskén K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002; 14:1-9.
12. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23:144-150.
13. Treves AJ, Ligumski M, Fuks Z, Haimovitz A, Rachmilewitz D. Prostaglandin E2 secretion by subsets of human peripheral blood monocytes. Immunopharmacology 1982; 4:267-276.
14. Rahmouni S, Aandahl EM, Nayjib B, Zeddou M, Giannini S, Verlaet M, et al. Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochem J 2004; 384:469-476.
15. Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78:2454-2459.
16. Johansson CC, Bryn T, Aandahl EM, Areklett MA, Aukrust P, Taskén K, et al. Short-term treatment of HIV-infected patients with COX-2 selective and non-selective inhibitor improves T cell function. AIDS 2004; 18:6-7.
17. Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, et al. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700. J Acquir Immune Defic Syndr 2003; 32:281-286.
18. Kran A-MB, Sørensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, Kvale D. HLA- and Dose-Dependent Immunogenicity of a Peptide-Based HIV-1 Immunotherapy Candidate (Vacc-4x). AIDS 2004; 18:1875-1883.
19. Kvale D, Kran A-MB, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, et al. Divergent in vitro and in vivo correlates of HIV-specific T cell responses during onset of HIV viraemia. AIDS 2005; 19:563-567.
20. Dybul M, Connors M, Fauci AS. The immunology of human immunodeficiency virus infection. In Principles and Practice of Infectious Diseases. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Elsevier Churchill Livingstone 2005:1527-1546.
21. Savarino A, Bottarel F, Malavasi F, Dianzini U. Role of CD38 in HIV-1 infection: an epiphenomonon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14:1079-1089.
22. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-355.
23. Goicoechea M, Miller C, Spina C, Currier J, Kemper C, Witt M, et al. Quantitative CD38 expression on CD8 T cells as a predictor of CD4 T-cell maintenance among patients failing salvage antiretroviral therapy. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 230].
24. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol 2002; 3:1061-1067.
25. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410:980-987.
26. Okie S. Raising the safety bar - The FDA's coxib meeting. N Engl J Med 2005; 352:1283-1285.